NASDAQ:ALBOAlbireo Pharma Stock Price, Forecast & News

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 41.9% and is now trading at $25.02. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Albireo Pharma.

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Albireo Pharma.

Albireo Pharma Inc (NASDAQ:ALBO) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.23) EPS for the quarter, missing the Zacks' consensus estimate of ($1.39) by $0.84. The biopharmaceutical company earned $1.55 million during the quarter, compared to analyst estimates of $1.19 million. Albireo Pharma had a negative return on equity of 72.82% and a negative net margin of 730.55%. View Albireo Pharma's earnings history.

6 brokers have issued 1-year price targets for Albireo Pharma's stock. Their forecasts range from $39.00 to $62.00. On average, they expect Albireo Pharma's share price to reach $52.60 in the next twelve months. This suggests a possible upside of 110.2% from the stock's current price. View analysts' price targets for Albireo Pharma.

Press coverage about ALBO stock has trended positive on Friday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Albireo Pharma earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Albireo Pharma.

Some companies that are related to Albireo Pharma include BELLUS Health (BLUSF), Zogenix (ZGNX), Revance Therapeutics (RVNC), Passage Bio (ZNTL), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), ZEALAND PHARMA/S (ZEAL), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Kiniksa Pharmaceuticals (KNSA), Innoviva (INVA), Karyopharm Therapeutics (KPTI), Tricida (TCDA) and Arvinas (ARVN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), Exelixis (EXEL), Palatin Technologies (PTN), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Viking Therapeutics (VKTX), Arcturus Therapeutics (ARCT), Alibaba Group (BABA) and Cornerstone Total Return Fund (CRF).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $25.02.

Albireo Pharma has a market capitalization of $374.80 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.

The official website for Albireo Pharma is www.albireopharma.com.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]